Research graph
References from Can low-burden HIV pre-exposure prophylaxis become affordable in low- and middle-income countries?. Local targets link to admitted publications; unresolved targets remain external evidence.
The estimated cost of MK-8527 produced at scale for once-monthly oral HIV pre-exposure prophylaxis in low- and middle-income countries
10.1097/qad.0000000000004487 · 2026 · External reference
Agreements to provide affordable lenacapavir
10.1016/j.lanmic.2025.101317 · 2026 · External reference
PURPOSE 1 Study Team. Twice-yearly lenacapavir or daily F/TAF for HIV prevention in cisgender women
10.1056/nejmoa2407001 · 2024 · External reference
PURPOSE 2 Study Team. Twice-yearly lenacapavir for HIV prevention in men and gender-diverse persons
10.1056/nejmoa2411858 · 2025 · External reference
Global analysis of pre-exposure prophylaxis to need ratios in 2025
10.1097/qad.0000000000004589 · 2026 · External reference
Agreements to provide affordable lenacapavir
10.1016/j.lanmic.2025.101317 · ExternalCitation · doi-reference
PURPOSE 1 Study Team. Twice-yearly lenacapavir or daily F/TAF for HIV prevention in cisgender women
10.1056/nejmoa2407001 · ExternalCitation · doi-reference
PURPOSE 2 Study Team. Twice-yearly lenacapavir for HIV prevention in men and gender-diverse persons
10.1056/nejmoa2411858 · ExternalCitation · doi-reference
The estimated cost of MK-8527 produced at scale for once-monthly oral HIV pre-exposure prophylaxis in low- and middle-income countries
10.1097/qad.0000000000004487 · ExternalCitation · doi-reference
Global analysis of pre-exposure prophylaxis to need ratios in 2025
10.1097/qad.0000000000004589 · ExternalCitation · doi-reference
